Omeros Corporation’s (OMER) “Buy” Rating Reaffirmed at Cantor Fitzgerald
Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Monday. They presently have a $21.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 176.32% from the stock’s current price.
Other equities analysts have also recently issued research reports about the company. S&P Equity Research upped their price target on Omeros Corporation from $7.65 to $8.63 in a report on Monday. WBB Securities restated a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a report on Monday. Maxim Group reduced their target price on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Wedbush reiterated an “outperform” rating and set a $56.00 target price (down from $62.00) on shares of Omeros Corporation in a research note on Thursday, August 11th. Finally, Zacks Investment Research cut Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.45.
Shares of Omeros Corporation (NASDAQ:OMER) traded up 3.54% during midday trading on Monday, hitting $7.60. 3,939,905 shares of the company were exchanged. The stock’s market capitalization is $298.63 million. The company has a 50-day moving average price of $10.60 and a 200-day moving average price of $11.73. Omeros Corporation has a 52-week low of $7.26 and a 52-week high of $16.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/omeros-corporations-omer-buy-rating-reaffirmed-at-cantor-fitzgerald.html
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.18. The company earned $10 million during the quarter, compared to analysts’ expectations of $9.80 million. The firm’s revenue was up 212.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.44) EPS. On average, analysts forecast that Omeros Corporation will post ($1.55) EPS for the current year.
In related news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the sale, the vice president now directly owns 179,597 shares of the company’s stock, valued at approximately $1,959,403.27. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the sale, the vice president now directly owns 179,497 shares in the company, valued at $2,074,985.32. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Ingalls & Snyder LLC purchased a new stake in Omeros Corporation during the second quarter valued at about $46,441,000. Bank of Montreal Can purchased a new stake in Omeros Corporation during the second quarter valued at about $17,641,000. State Street Corp raised its stake in Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock valued at $9,274,000 after buying an additional 126,595 shares in the last quarter. Chicago Equity Partners LLC purchased a new stake in Omeros Corporation during the second quarter valued at about $961,000. Finally, GSA Capital Partners LLP purchased a new stake in Omeros Corporation during the second quarter valued at about $762,000. 48.04% of the stock is currently owned by institutional investors and hedge funds.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.